

## **Ribon Therapeutics Secures \$50 Million in Growth Capital from K2 HealthVentures**

- Investment to support ongoing clinical studies of RBN-2397 and RBN-3143 and expansion of BEACON<sup>+</sup> platform -

Cambridge, MA – April 26, 2022 – Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced a \$50 million debt financing facility from K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm. Proceeds will be used to continue clinical and preclinical development of Ribon’s portfolio of selective, small molecule inhibitors to NAD<sup>+</sup>-utilizing enzymes.

“We are thrilled to partner with K2HV and to secure this financing which provides us with additional resources and flexibility as we advance clinical development of RBN-2397 and RBN-3143 and evaluate a number of preclinical programs derived from our BEACON<sup>+</sup> platform,” said Prakash Raman, Ph.D., President and Chief Executive Officer, Ribon Therapeutics. “We are well positioned to continue growing our programs and value the support of K2HV as we advance the field of cellular stress support pathway biology.”

“Ribon is at the forefront of the emerging field of cellular stress support pathway biology and is building a compelling portfolio of small molecule modulators of NAD<sup>+</sup>-utilizing enzymes with its BEACON<sup>+</sup> platform,” added Parag Shah, Founding Managing Director and Chief Executive Officer at K2HV. “This investment follows our commitment to supporting innovative science led by tenured management teams with the drive to develop novel, first-in-class therapeutics with a patient-centric approach.”

Ribon, named a “Fierce 15” Biotech Company by Fierce Biotech in 2021, is pioneering the discovery and development of first-in-class precision therapies targeting stress support pathways in cancer and inflammation for patients with limited options. By leveraging its proprietary BEACON<sup>+</sup> platform, the Company is building a pipeline of selective, small molecule inhibitors to numerous NAD<sup>+</sup>-utilizing enzymes. Ribon’s lead program is RBN-2397, a PARP7 inhibitor in clinical development for the treatment of cancer. RBN-2397 is currently in a Phase 1 clinical trial as a monotherapy in patients with advanced solid tumors and in a Phase 1b/2 clinical trial in combination with pembrolizumab. Ribon is also advancing a second clinical candidate, RBN-3143, a potent and selective PARP14 inhibitor for the treatment of patients with inflammatory diseases. A first-in-human Phase 1 study of RBN-3143 was recently initiated in the healthy volunteer portion of the trial.

### **About Ribon Therapeutics**

Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. Ribon’s portfolio includes two oral first-in-class clinical programs, RBN-2397 (a PARP7 inhibitor) and RBN-3143 (a PARP14 inhibitor), targeting broad indications in oncology and inflammatory diseases. The company explores novel areas of biology to develop effective treatments for patients with limited therapeutic options and has active clinical programs in oncology and inflammatory disease. Leveraging our proprietary BEACON<sup>+</sup> (Blocking the Enzyme Activity Component of NAD<sup>+</sup>) platform, we are building a pipeline of selective, small molecule inhibitors to numerous NAD<sup>+</sup>-utilizing enzymes, beginning with monoARTs (mono-ADP-ribosyltransferase),

which have applications across multiple therapeutic areas. Ribon is located in Cambridge, Massachusetts. For more information, visit <https://ribontx.com/>.

### **About K2 HealthVentures**

K2 HealthVentures is an alternative investment firm focused on providing flexible, long-term financing solutions to innovative private and public companies in the life sciences and healthcare industries. The investment team comprises collaborative, experienced professionals with diverse backgrounds in finance and operations, as well as deep domain knowledge across various healthcare sectors. A uniquely flexible, permanent capital structure enables the firm to provide creative, adaptive financing solutions and meet the evolving capital needs of its portfolio companies as they grow. K2HV is driven by dual goals of Profit and Purpose—aiming to fuel the growth of innovative companies that will ultimately improve the lives of patients and giving a percentage of investment profits back to underserved areas in healthcare. [www.k2hv.com](http://www.k2hv.com)

### **Contact:**

MacDougall Advisors  
Nick Chang  
781-235-3060  
nchang@macdougall.bio